REAL-WORLD DATA ANALYSIS OF ONCOLOGICAL DRUG FUNDING AND ACCESS HETEROGENEITY IN THE BRAZILIAN PUBLIC HEALTH SYSTEM (SUS)
Author(s)
Ricardo R.a. Fernandes, PhD1, Cid M. Vianna, PhD1, Mozar B. da Silva, PhD1, Amanda O. Lyrio, Msc2, Ana Carolina de Almeida, PhD2.
1Social Medicine Institute, Public Health, Rio de Janeiro, Brazil, 2Health Ministry, Brasília, Brazil.
1Social Medicine Institute, Public Health, Rio de Janeiro, Brazil, 2Health Ministry, Brasília, Brazil.
OBJECTIVES: This study aimed to develop a software solution to monitor the reinbursment and utilization of oncological therapies in the Brazilian Public Health System (SUS), using real-world evidence from public databases to check the adoption of National Commission for the Incorporation of Technologies (CONITEC) drug recommendation across the country.
METHODS: Data on oncological treatment procedures from 2008 to 2024 were collected and migrated to a PostgreSQL database. An automated classification system was created to map drug nomenclatures in the Procedure Reimbursement Authorization (APAC) records to seven specific CONITEC recommendations in breast, prostate, and renal cancer. The database was enriched with temporal data, including recommendation, clinical guidelines publication, and reimbursement value change dates. The analysis focused on the evolution of drug diffusion in the SUS, identifying the number of authorized procedures that used drugs according to CONITEC recommendations.
RESULTS: Six interactive dashboards were built, allowing detailed longitudinal tracking of drug adoption. The dashboards illustrate monthly procedure volumes and the percentage of them using the recommended drugs versus non-recommended alternatives. Data revealed that hormone therapies were the only recommendations that were totally followed. Utilization rates for other drugs varied significantly: Sunitinib and Pazopanib (renal cancer) were used in 75% of procedures, while Pertuzumab (breast) and Abiraterone were found in 50%. Notably, TDM-1 and Cyclin Inhibitors (breast can) recommendations were not followed (0%). The geographical and administrative filters revealed significant and quantifiable heterogeneity in the utilization patterns across different regions and states. Results can be accessed at: https://www.observaonco.com.br.
CONCLUSIONS: The developed platform provides an unprecedented tool for monitoring the real-world incorporation of oncological technologies in SUS, transforming raw, complex public data into actionable insights. The observed heterogeneity in drug adoption highlights potential disparities in access and implementation across different regions and health establishments. This system offers a critical resource for to evaluate the effectiveness of reimbursement policies.
METHODS: Data on oncological treatment procedures from 2008 to 2024 were collected and migrated to a PostgreSQL database. An automated classification system was created to map drug nomenclatures in the Procedure Reimbursement Authorization (APAC) records to seven specific CONITEC recommendations in breast, prostate, and renal cancer. The database was enriched with temporal data, including recommendation, clinical guidelines publication, and reimbursement value change dates. The analysis focused on the evolution of drug diffusion in the SUS, identifying the number of authorized procedures that used drugs according to CONITEC recommendations.
RESULTS: Six interactive dashboards were built, allowing detailed longitudinal tracking of drug adoption. The dashboards illustrate monthly procedure volumes and the percentage of them using the recommended drugs versus non-recommended alternatives. Data revealed that hormone therapies were the only recommendations that were totally followed. Utilization rates for other drugs varied significantly: Sunitinib and Pazopanib (renal cancer) were used in 75% of procedures, while Pertuzumab (breast) and Abiraterone were found in 50%. Notably, TDM-1 and Cyclin Inhibitors (breast can) recommendations were not followed (0%). The geographical and administrative filters revealed significant and quantifiable heterogeneity in the utilization patterns across different regions and states. Results can be accessed at: https://www.observaonco.com.br.
CONCLUSIONS: The developed platform provides an unprecedented tool for monitoring the real-world incorporation of oncological technologies in SUS, transforming raw, complex public data into actionable insights. The observed heterogeneity in drug adoption highlights potential disparities in access and implementation across different regions and health establishments. This system offers a critical resource for to evaluate the effectiveness of reimbursement policies.
Conference/Value in Health Info
2026-05, ISPOR 2026, Philadelphia, PA, USA
Value in Health, Volume 29, Issue S6
Code
RWD56
Topic
Real World Data & Information Systems
Disease
SDC: Oncology, SDC: Reproductive & Sexual Health, SDC: Urinary/Kidney Disorders